82 related articles for article (PubMed ID: 9648590)
1. Retinoblastoma protein expression in ovarian epithelial neoplasms.
Niemann TH; Trgovac TL; McGaughy VR; Lewandowski GS; Copeland LJ
Gynecol Oncol; 1998 Jun; 69(3):214-9. PubMed ID: 9648590
[TBL] [Abstract][Full Text] [Related]
2. Loss of heterozygosity on chromosome 13 is common only in the biologically more aggressive subtypes of ovarian epithelial tumors and is associated with normal retinoblastoma gene expression.
Kim TM; Benedict WF; Xu HJ; Hu SX; Gosewehr J; Velicescu M; Yin E; Zheng J; D'Ablaing G; Dubeau L
Cancer Res; 1994 Feb; 54(3):605-9. PubMed ID: 8306317
[TBL] [Abstract][Full Text] [Related]
3. Differences in p16 gene methylation and expression in benign and malignant ovarian tumors.
McCluskey LL; Chen C; Delgadillo E; Felix JC; Muderspach LI; Dubeau L
Gynecol Oncol; 1999 Jan; 72(1):87-92. PubMed ID: 9889036
[TBL] [Abstract][Full Text] [Related]
4. Retinoblastoma protein expression in endometrial hyperplasia and carcinoma.
Niemann TH; Yilmaz AG; McGaughy VR; Vaccarello L
Gynecol Oncol; 1997 May; 65(2):232-6. PubMed ID: 9159330
[TBL] [Abstract][Full Text] [Related]
5. Evidence of functional RB protein in epithelial ovarian carcinomas despite loss of heterozygosity at the RB locus.
Dodson MK; Cliby WA; Xu HJ; DeLacey KA; Hu SX; Keeney GL; Li J; Podratz KC; Jenkins RB; Benedict WF
Cancer Res; 1994 Feb; 54(3):610-3. PubMed ID: 8306318
[TBL] [Abstract][Full Text] [Related]
6. Frequent down-regulation and lack of mutation of the KAI1 metastasis suppressor gene in epithelial ovarian carcinoma.
Liu FS; Dong JT; Chen JT; Hsieh YT; Ho ES; Hung MJ
Gynecol Oncol; 2000 Jul; 78(1):10-5. PubMed ID: 10873402
[TBL] [Abstract][Full Text] [Related]
7. Decreased luteinizing hormone receptor mRNA expression in human ovarian epithelial cancer.
Lu JJ; Zheng Y; Kang X; Yuan JM; Lauchlan SC; Pike MC; Zheng W
Gynecol Oncol; 2000 Nov; 79(2):158-68. PubMed ID: 11063638
[TBL] [Abstract][Full Text] [Related]
8. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium.
Schmandt RE; Broaddus R; Lu KH; Shvartsman H; Thornton A; Malpica A; Sun C; Bodurka DC; Gershenson DM
Cancer; 2003 Aug; 98(4):758-64. PubMed ID: 12910520
[TBL] [Abstract][Full Text] [Related]
9. Expression of survivin is associated with malignant potential in epithelial ovarian carcinoma.
Takai N; Miyazaki T; Nishida M; Nasu K; Miyakawa I
Int J Mol Med; 2002 Aug; 10(2):211-6. PubMed ID: 12119561
[TBL] [Abstract][Full Text] [Related]
10. Promoter hypermethylation profile of ovarian epithelial neoplasms.
Makarla PB; Saboorian MH; Ashfaq R; Toyooka KO; Toyooka S; Minna JD; Gazdar AF; Schorge JO
Clin Cancer Res; 2005 Aug; 11(15):5365-9. PubMed ID: 16061849
[TBL] [Abstract][Full Text] [Related]
11. Expression and amplification of eIF-5A2 in human epithelial ovarian tumors and overexpression of EIF-5A2 is a new independent predictor of outcome in patients with ovarian carcinoma.
Yang GF; Xie D; Liu JH; Luo JH; Li LJ; Hua WF; Wu HM; Kung HF; Zeng YX; Guan XY
Gynecol Oncol; 2009 Feb; 112(2):314-8. PubMed ID: 19054548
[TBL] [Abstract][Full Text] [Related]
12. Histologically benign or low-grade malignant tumors adjacent to high-grade ovarian carcinomas contain molecular characteristics of high-grade carcinomas.
Zheng J; Wan M; Zweizig S; Velicescu M; Yu MC; Dubeau L
Cancer Res; 1993 Sep; 53(18):4138-42. PubMed ID: 8364906
[TBL] [Abstract][Full Text] [Related]
13. Analysis of telomerase activity in ovarian cystadenomas, low-malignant-potential tumors, and invasive carcinomas.
Datar RH; Naritoku WY; Li P; Tsao-Wei D; Groshen S; Taylor CR; Imam SA
Gynecol Oncol; 1999 Sep; 74(3):338-45. PubMed ID: 10479490
[TBL] [Abstract][Full Text] [Related]
14. Dynamic alterations of the extracellular environment of ovarian surface epithelial cells in premalignant transformation, tumorigenicity, and metastasis.
Capo-Chichi CD; Smith ER; Yang DH; Roland IH; Vanderveer L; Cohen C; Hamilton TC; Godwin AK; Xu XX
Cancer; 2002 Oct; 95(8):1802-15. PubMed ID: 12365030
[TBL] [Abstract][Full Text] [Related]
15. [P53-status in primary ovarian carcinomas, ovarian metastases of neoplasms in other sites and benign ovarian tumors: predictive value in comparison to histopathological parameters].
Casper F; Weikel W; Schaffrath M; Kuner RP; Hoffmann G; Pollow B; Pollow K
Zentralbl Gynakol; 2000; 122(3):153-9. PubMed ID: 10756599
[TBL] [Abstract][Full Text] [Related]
16. [Expression and significance of tumor suppressor gene WAF1 in epithelial ovarian neoplasms].
Cao L; Yang Z; Li X
Hunan Yi Ke Da Xue Xue Bao; 1998; 23(6):602-4. PubMed ID: 10806783
[TBL] [Abstract][Full Text] [Related]
17. Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei.
McKenney JK; Soslow RA; Longacre TA
Am J Surg Pathol; 2008 May; 32(5):645-55. PubMed ID: 18344868
[TBL] [Abstract][Full Text] [Related]
18. Expression of extracellular matrix proteins in ovarian serous tumors.
Salani R; Neuberger I; Kurman RJ; Bristow RE; Chang HW; Wang TL; Shih IeM
Int J Gynecol Pathol; 2007 Apr; 26(2):141-6. PubMed ID: 17413980
[TBL] [Abstract][Full Text] [Related]
19. CAS (cellular apoptosis susceptibility) gene expression in ovarian carcinoma: Correlation with 20q13.2 copy number and cyclin D1, p53, and Rb protein expression.
Peiró G; Diebold J; Löhrs U
Am J Clin Pathol; 2002 Dec; 118(6):922-9. PubMed ID: 12472286
[TBL] [Abstract][Full Text] [Related]
20. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
